Compare MNDY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDY | ACAD |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.8B |
| IPO Year | 2021 | 2000 |
| Metric | MNDY | ACAD |
|---|---|---|
| Price | $81.55 | $25.59 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 22 |
| Target Price | ★ $167.65 | $30.55 |
| AVG Volume (30 Days) | 928.5K | ★ 1.8M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $726,437,000.00 |
| Revenue This Year | $20.70 | $18.80 |
| Revenue Next Year | $16.48 | $11.70 |
| P/E Ratio | ★ $34.38 | $1,272.50 |
| Revenue Growth | N/A | ★ 40.45 |
| 52 Week Low | $57.50 | $19.69 |
| 52 Week High | $296.94 | $28.35 |
| Indicator | MNDY | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 64.39 |
| Support Level | $67.84 | $25.40 |
| Resistance Level | $88.48 | $27.79 |
| Average True Range (ATR) | 4.12 | 0.93 |
| MACD | 1.00 | 0.05 |
| Stochastic Oscillator | 70.57 | 62.74 |
Monday.com Ltd is an artificial intelligence work platform that runs and orchestrates the core of all work. The platform democratizes access to software, including AI, enabling organizations to easily build applications and work management tools that fit their needs. The cloud-based platform is a no-code and low-code framework built from modular building blocks that are simple enough for anyone to use, yet powerful enough to drive core business across any organization. The platform also integrates with other systems and applications, creating a connective layer for organizations that links departments and bridges information silos. In addition to the core products, it introduced four core Al work capabilities: monday sidekick, monday vibe, monday agents, and workflows.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.